Oncology

Driving post-COVID cancer treatment with innovation and dedication

Click here

Immunotherapy: building the fourth pillar of cancer treatment

Cancer immunotherapy is a staple of modern oncology. But how did the concept move from from far-fetched concept to medical reality?

Click here

Realising the promise of cancer vaccines

Therapeutic cancer vaccine trials have an opportunity to leverage recent interest in vaccine technology to make headway in oncology, says Advanced Clinical’s Christopher Oelkrug

Click here

The pharma world at your fingertips

Daily and weekly email newsletters from pharmaphorum – insights and analysis on the big trends shaping healthcare and the pharmaceutical industry

Click here

Phesi’s Dr Gen Li: new approaches to clinical trials in cancer

Founder and president of clinical development analytics company Phesi Dr Gen Li discusses prominent challenges and opportunities in oncology trials

Click here

The challenges and opportunities for kidney cancer care recovery

Kidney cancer care in the UK is reaching a tipping point. IPSEN’s Siew Kwan Chang discusses the need for dedicated NICE guidance for kidney cancer

Click here

Diversity by design: the importance of DE&I in oncology trials

Diversity is no longer an optional luxury in clinical research, explain Dr Stephen Keith and Nick Kenny from Syneos. But what can be done to improve DE&I in oncology trials?

Click here

The pharmaphorum podcast

Download exclusive interviews and discussions with senior pharma and biotech executives

Click here

Realising the potential of genomic testing across oncology

The UK has a rich history of advancing genomics research, which has opened the door for routine genomic testing for cancer, as IQVIA’s Orlaith Brennan and Dr Julia Beguería explain

Click here

New horizons in breast cancer care

Recent progress in immunotherapy, targeted therapies, and genetic testing has allowed physicians to treat breast cancer more precisely, says Daiichi Sankyo’s Markus Kosch

Click here

ASCO 2022: Checkpoint inhibitors, Enhertu in spotlight

pharmaphorum editor in chief Jonah Comstock rounds up key developments from the American Society of Clinical Oncology’s first in-person conference since COVID began

Click here

Frontiers Health 2022

Frontiers Health returns for a two-day hybrid event, with super early bird passes now on sale

Click here

Subscribe to future editions of Deep Dive

Sign-up to receive the next issue of pharmaphorum’s digital magazine for pharma direct to your inbox

Click here

Video
Share

Your name

Your e-mail

Name receiver

E-mail address receiver

Your message

Send

Share

E-mail

Facebook

Twitter

LinkedIn

Contact

Send